Thema: News: Erfolgreiche Brachytherapie
News: Erfolgreiche Brachytherapie
Tom[a]
14.02.2002 11:22:16
Swiss Med Wkly 2001 Nov 10;131(43-44):640-644
Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA(0)-D-Phe(1)-Tyr(3)-octreotide (DOTATOC).
Merlo A, Hofer S, Eichhorn K, Freitag P, Reubi J, Mueller-Brand J, Maecke H.
Neurosurgical Clinic, University Hospitals, Spitalstrasse 21, Basel, 4031, CH.
We present the therapeutic effect of diffusible brachytherapy (dBT), an innovative approach for the management of symptomatic low grade gliomas [1]. This protocol uses a radiolabelled small diffusible peptidic vector which is a somatostatin analogue to target somatostatin type 2 (sst--2) receptors. The stable radioconjugate [90Y]-DOTA(0)-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) is repeatedly injected via catheters placed into the resection cavity or into tumour nodules. We report on the four year follow-up after initiation of dBT to treat progressive disease in a patient with a complex eleven year history of fibrillary low-grade astrocytoma. The radiopharmakon was not only locally injected into the resection cavity following debulking surgery, but also administered by slow infusion technique to target recurrent and infiltrative tumour zones in the subventricular region around the inferior and posterior horns. In conclusion, peptidic vector based dBT was found to be safe, of mild and transitory toxicity, and effective in long-term tumour control.
Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA(0)-D-Phe(1)-Tyr(3)-octreotide (DOTATOC).
Merlo A, Hofer S, Eichhorn K, Freitag P, Reubi J, Mueller-Brand J, Maecke H.
Neurosurgical Clinic, University Hospitals, Spitalstrasse 21, Basel, 4031, CH.
We present the therapeutic effect of diffusible brachytherapy (dBT), an innovative approach for the management of symptomatic low grade gliomas [1]. This protocol uses a radiolabelled small diffusible peptidic vector which is a somatostatin analogue to target somatostatin type 2 (sst--2) receptors. The stable radioconjugate [90Y]-DOTA(0)-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) is repeatedly injected via catheters placed into the resection cavity or into tumour nodules. We report on the four year follow-up after initiation of dBT to treat progressive disease in a patient with a complex eleven year history of fibrillary low-grade astrocytoma. The radiopharmakon was not only locally injected into the resection cavity following debulking surgery, but also administered by slow infusion technique to target recurrent and infiltrative tumour zones in the subventricular region around the inferior and posterior horns. In conclusion, peptidic vector based dBT was found to be safe, of mild and transitory toxicity, and effective in long-term tumour control.
Tom[a]
